Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 24;9(5):428. doi: 10.3390/vaccines9050428

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Results of the ex vivo Interferon-γ ELISpot after the first vaccination. (A) ELISpot wells showing spot counts obtained from pre- and post-vaccination PBMC samples tested against each of the specified vaccine peptides (n = 10, in triplicate). The negative control (ctrl.—DMSO and water) was tested in six replicate wells and the positive control (+ ctrl.—phytohemagglutinin) in duplicate wells. The images representing the ELISpot wells were rearranged for this illustration. (B) Graph of spot numbers for the three SARS-CoV-2-derived HLA-DR peptides. The mean and SD are shown from three technical replicates. Abbreviations: CMV—cytomegalovirus, ctrl.—control, DMSO—dimethyl sulfoxide, env—envelope protein, nuc—nucleoprotein, pre-vac—36 days before vaccination, post-vac—19 days after vaccination, and SARS-CoV-2—severe acute respiratory syndrome coronavirus 2.